Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (August 2021)
27 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, August 2021
Slide 1: Annual Shareholders' Meeting 2021
Annual Shareholders’ Meeting 2021
Slide 2: Online Help
Online Help A HUMAN 7 tweRe, roceTuen RESPONSE new rreounre Annual Shareholders’ Meeting 2021 Ne of meeting Annual report Fisher &Paykel HEALTHCARE
Slide 3: Your Board
Your Board Scott St John Lewis Gradon Sir Michael Daniell Pip Greenwood Geraldine McBride Neville Mitchell Donal O’Dwyer
Slide 4: Agenda
Agenda • Chair’s Address and Board Subcommittee Updates • Managing Director and Chief Executive Officer’s Review • Financial Statements • Resolutions • Voting • General Questions
Slide 5: FY2021 Financial Highlights
FY2021 Financial Highlights Operating $1.97B ↑ 56% Revenue Net Profit After Tax $524.2M ↑ 82% Dividend 38.00cps ↑ 38%
Slide 6: FY2021 Revenue by Product Group
FY2021 Revenue by Product Group Homecare Hospital 24% 76% OF OPERATING REVENUE OF OPERATING REVENUE Distributed & Other <1% OF OPERATING REVENUE
Slide 7: Hospital Overview
Overview Overview Hospital Overview Overview F&P MR850TM Optiflow+
Slide 8: Hospital Product Group FY21 Result
Hospital Product Group FY21 Result $1.5B 1498.1 Revenue FY21 Revenue Growth ↑ 87% 801.3 NZ$ 642.3 572.1 ↑ 94% 500.4 Constant Currency FY17 FY18 FY19 FY20 FY21
Slide 9: Homecare
Homecare F&P MyAirvo2TM Optiflow+
Slide 10: Homecare Product Group FY21 Result
Homecare Product Group FY21 Result Revenue $466M 465.6 457.3 421.4 398.1 381.5 FY21 Revenue Growth NZ$ ↑ 2% Constant Currency ↑ 4% FY17 FY18 FY19 FY20 FY21
Slide 11: Gross and Operating Margins
Gross and Operating Margins Gross Margin Operating (EBIT) Margin 70% 40% 60% 35% 30% 50% 25% 40% 20% 30% 15% 20% 10% 10% 5% 0% 0% 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 Long Term Gross Margin Target – 65% Long Term Operating Margin Target – 30%
Slide 12: Research and development - $136.7 million investment
See if we can replace, we used this one last year Research and development - $136.7 million investment
Slide 13: 6,000+ people
6,000+ people Fisher 3 Payal
Slide 14: Profit-sharing bonus - $29 million
Profit-sharing bonus - $29 million
Slide 15: Community
Community Fisher & Paykel Healthcare Foundation NZ $20MILLION
Slide 16: FY22 Trading Update
FY22 Trading Update First four months of FY22 • Revenue $583M, 2% below the prior comparable period in constant currency • Hospital product group − Revenue down 3% cc from prior comparable period − 13% decline in hardware sales from prior comparable period − Hardware revenue remained elevated − Cons
Slide 17: Outlook for the remainder of FY22
Outlook for the remainder of FY22 For the remainder of the 2022 financial year*: • No quantitative guidance provided given continuing uncertainties related to COVID-19 • Hospital hardware revenue not expected to continue at elevated levels • Hospital consumables sales will continue to be impacted by
Slide 18: Financial Statements
Financial Statements • Opportunity for shareholders to ask any questions specifically on the financial statements, the auditor’s report or the company’s 2021 annual report. • There will be an opportunity to ask any general questions once all items on the agenda have been considered.
Slide 19: Resolutions
Resolutions 1. Re-election of Scott St John as Director 2. Re-election of Sir Michael Daniell as Director 3. Auditor’s Remuneration 4. Issue of Performance Share Rights 5. Issue of Options
Slide 20: How to Vote Online
How to Vote Online Voting box Question box
Slide 21: Resolution 1: Re-election of Scott St John
Resolution 1: Re-election of Scott St John That Scott St John, who retires by rotation and, being eligible, offers himself for re- election, be re-elected as a director of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services helpline 0800 200 220
Slide 22: Resolution 2: Re-election of Sir Michael Daniell
Resolution 2: Re-election of Sir Michael Daniell That Sir Michael Daniell, who retires by rotation and, being eligible, offers himself for re-election, be re-elected as a director of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services helpline 0800 200 220
Slide 23: Resolution 3: Auditor's Remuneration
Resolution 3: Auditor’s Remuneration That the Directors be authorised to fix the fees and expenses of PwC as the Company’s auditor. Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services helpline 0800 200 220
Slide 24: Resolution 4: Issue of Performance Share Rights
Resolution 4: Issue of Performance Share Rights That approval be given for the issue of up to 60,000 performance share rights under the Fisher & Paykel Healthcare Performance Share Rights Plan to Lewis Gradon, Managing Director and Chief Executive Officer of the Company. Click “Submit Vote” to lodge
Slide 25: Resolution 5: Issue of Options
Resolution 5: Issue of Options That approval be given for the issue of up to 190,000 options under the Fisher & Paykel Healthcare 2019 Share Option Plan to Lewis Gradon, Managing Director and Chief Executive Officer of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the Link Mar
Slide 26: Questions?
Questions? Fisher &Paykel HEALTHCARE
Slide 27: Meeting concluded
Overview Overview This concludes the 2021 Annual Shareholders’ Meeting. Thank you for attending. Overview
Fisher & Paykel Healthcare — Shareholder Meeting (August 2021) on 6ix